![Beatriz Palacios-Izquierdo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Beatriz Palacios-Izquierdo
Keine laufenden Positionen mehr
Profil
Beatriz Palacios-Izquierdo worked as a Development Director at Traslational Cancer Drugs Pharma SL, a Clinical Project Manager at Almirall SA, the Chief of the Department for Clinical Development at Chemo Ibérica SA, and a Senior Scientist for Clinical Research at Novartis Pharma AG.
She earned a doctorate degree from the University of Salamanca in 1994.
Ehemalige bekannte Positionen von Beatriz Palacios-Izquierdo
Unternehmen | Position | Ende |
---|---|---|
Traslational Cancer Drugs Pharma SL
![]() Traslational Cancer Drugs Pharma SL BiotechnologyHealth Technology Traslational Cancer Drugs Pharma SL engages in the discovery and development of therapeutic solutions for the treatment of cancer. Its TCD-717 choline kinase alpha inhibitor is an intravenously-administered small molecule designed to target cancer cells. It also provides technology in-licensing and out-licensing services. The company was founded by Juan Carlos San Juan on July 29, 2005 and is headquartered in Valladolid, Spain. | Corporate Officer/Principal | - |
ALMIRALL, S.A. | Corporate Officer/Principal | - |
Chemo Ibérica SA
![]() Chemo Ibérica SA Pharmaceuticals: MajorHealth Technology Chemo Ibérica SA develops and distributes pharmaceutical products. It also produces veterinery finished products, raw materials, intermediate products from synthesis and other fine chemicals. Its activities are grouped under chemistry, generics, healthcare, veterinery and agrochemicals. The company also operates in India, China, Italy, Guatemala, Switzerland, Hungary, Argentina, Belgium & Luxembourg through subsidiaries, joint ventures and commercial offices. Chemo Iberica was founded in 1977 and is headquartered in Madrid, Spain. | Technik-/Wissenschafts-/F&E-Leiter | - |
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Ausbildung von Beatriz Palacios-Izquierdo
University of Salamanca | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ALMIRALL, S.A. | Health Technology |
Private Unternehmen | 3 |
---|---|
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Chemo Ibérica SA
![]() Chemo Ibérica SA Pharmaceuticals: MajorHealth Technology Chemo Ibérica SA develops and distributes pharmaceutical products. It also produces veterinery finished products, raw materials, intermediate products from synthesis and other fine chemicals. Its activities are grouped under chemistry, generics, healthcare, veterinery and agrochemicals. The company also operates in India, China, Italy, Guatemala, Switzerland, Hungary, Argentina, Belgium & Luxembourg through subsidiaries, joint ventures and commercial offices. Chemo Iberica was founded in 1977 and is headquartered in Madrid, Spain. | Health Technology |
Traslational Cancer Drugs Pharma SL
![]() Traslational Cancer Drugs Pharma SL BiotechnologyHealth Technology Traslational Cancer Drugs Pharma SL engages in the discovery and development of therapeutic solutions for the treatment of cancer. Its TCD-717 choline kinase alpha inhibitor is an intravenously-administered small molecule designed to target cancer cells. It also provides technology in-licensing and out-licensing services. The company was founded by Juan Carlos San Juan on July 29, 2005 and is headquartered in Valladolid, Spain. | Health Technology |